BUFFALO, NY – June 28, 2016 – OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq ComprehensiveSM panel, a 144…
Steve Anderson @Covance speaking at the Immuno-Oncology Frontiers conference: "How do we bring cutting-edge immunotherapies to the community?"
Key challenge in #immunotherapy is predicting which patients will respond to IO therapy, says Dr. Dutkowski of @Data4Cure #PMWC18
Later this week, OmniSeq will present four posters and have a booth at the ASCO-SITC meeting in San Francisco. Stop by, say hello and learn more about our work in immuno-oncology. #immunoonc18
New findings provide proof of concept for the rational combinatorial targeting of distinct populations in heterogeneous tumors & merit clinical validation of AXL-107-MMAE in both treatment-naive and drug-resistant #cancers in mono- or combination therapy: https://t.co/TZbdUbMW3L
The FDA has approved the PARP inhibitor olaparib for the treatment of patients with HER2-negative metastatic breast cancer (after chemotherapy/endocrine therapy) who have a germ line BRCA mutation detected using the companion diagnostic BRACAnalysis CDx: https://t.co/9FtIBE2T1O
On The Sentinel: In to I-O: First Contact, by Dr. Nils Rudqvist @WeillCornell https://t.co/ZgUPVVnib2 #AbscopalEffect #Cancer #Immunotherapy #blog
OmniSeq Comprehensive and Immune Report Card are both offered exclusively in the U.S. by LabCorp's Integrated Oncology unit.
Using exome sequencing or #CRISPR to find the genes that influence response to #cancer immunotherapy (and they converge!) ->★ chromatin